https://pharminent.com/week-in-review/week-in-review-intelligence-brief-may-30-2026/ 2026-05-30T21:40:35Z Pharminent en Week in Review • INTELLIGENCE BRIEF • May 30, 2026 2026-05-30T21:40:30Z Blog https://pharminent.com/membership-account/your-profile/ 2026-05-30T16:29:22Z Pharminent en Your Profile 2026-05-30T16:29:22Z Blog https://pharminent.com/membership-levels/ 2026-05-30T16:29:20Z Pharminent en Membership Levels 2026-05-30T16:29:20Z Blog https://pharminent.com/membership-checkout/membership-confirmation/ 2026-05-30T16:29:19Z Pharminent en Membership Confirmation 2026-05-30T16:29:19Z Blog https://pharminent.com/membership-account/membership-orders/ 2026-05-30T16:29:19Z Pharminent en Membership Orders 2026-05-30T16:29:19Z Blog https://pharminent.com/membership-checkout/ 2026-05-30T16:29:18Z Pharminent en Membership Checkout 2026-05-30T16:29:18Z Blog https://pharminent.com/membership-account/membership-cancel/ 2026-05-30T16:29:16Z Pharminent en Membership Cancel 2026-05-30T16:29:16Z Blog https://pharminent.com/membership-account/membership-billing/ 2026-05-30T16:29:14Z Pharminent en Membership Billing 2026-05-30T16:29:14Z Blog https://pharminent.com/membership-account/ 2026-05-30T16:29:12Z Pharminent en Membership Account 2026-05-30T16:29:12Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-may-29-2026/ 2026-05-30T15:27:16Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • May 29, 2026 2026-05-30T15:27:12Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-may-29-2026/ 2026-05-30T15:22:05Z Pharminent en Oncology Intelligence Digest • May 29, 2026 2026-05-30T15:22:00Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-29-2026/ 2026-05-29T19:35:15Z Pharminent en Strategic News Watch • May 29, 2026 2026-05-29T19:35:11Z Blog https://pharminent.com/asco-bms-hails-compelling-phase-3-celmod-readout/ 2026-05-29T17:19:02Z Pharminent en ASCO: BMS hails "compelling" phase 3 celmod readout 2026-05-29T15:20:45Z Blog https://pharminent.com/summits-pd-1-vegf-to-take-center-stage-at-asco-with-wide-impact-for-peers/ 2026-05-29T17:19:07Z Pharminent en Summit's PD-1/VEGF to take center stage at ASCO, with wide impact for peers 2026-05-29T14:17:35Z Blog https://pharminent.com/replimune-gives-cancer-immunotherapy-a-third-try-after-fda-leadership-shakeup/ 2026-05-30T21:27:34Z Pharminent en Replimune gives cancer immunotherapy a third try after FDA leadership shakeup 2026-05-29T13:33:07Z Blog https://pharminent.com/fda-delays-verdict-on-berens-rare-disease-drug-by-three-months/ 2026-05-30T21:31:14Z Pharminent en FDA delays verdict on Beren's rare disease drug by three months 2026-05-29T11:57:50Z Blog https://pharminent.com/pfizer-bets-up-to-10-5b-in-12-candidate-cancer-collab-with-chinas-innovent/ 2026-05-29T17:19:09Z Pharminent en Pfizer bets up to $10.5B in 12-candidate cancer collab with China's Innovent 2026-05-29T11:04:01Z Blog https://pharminent.com/gsks-nucala-secures-nice-copd-endorsement/ 2026-05-29T21:23:52Z Pharminent en GSK's Nucala secures NICE COPD endorsement 2026-05-29T10:26:43Z Blog https://pharminent.com/ahead-of-asco-data-drop-az-gets-key-imfinzi-approval/ 2026-05-29T17:19:11Z Pharminent en Ahead of ASCO data drop, AZ gets key Imfinzi approval 2026-05-29T10:01:58Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-may-28-2026/ 2026-05-29T02:44:03Z Pharminent en Rare Disease & Gene Therapy Digest • May 28, 2026 2026-05-29T02:43:59Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-28-2026/ 2026-05-28T18:43:55Z Pharminent en Strategic News Watch • May 28, 2026 2026-05-28T18:43:50Z Blog https://pharminent.com/medicare-advantage-out-of-pocket-limits-variation-and-trends/ 2026-05-29T17:30:21Z Pharminent en Medicare Advantage Out-of-Pocket Limits: Variation and Trends 2026-05-28T17:17:28Z Blog https://pharminent.com/gsk-ionis-unveil-data-for-hepatitis-b-drug-touted-as-functional-cure/ 2026-05-29T17:30:32Z Pharminent en GSK, Ionis unveil data for hepatitis B drug touted as 'functional cure' 2026-05-28T16:01:00Z Blog https://pharminent.com/cvs-obesity-drug-deal-puts-lilly-on-equal-footing-with-novo/ 2026-05-28T15:34:46Z Pharminent en CVS obesity drug deal puts Lilly on equal footing with Novo 2026-05-28T15:09:00Z Blog https://pharminent.com/france-first-eu-country-to-cover-obesity-drugs/ 2026-05-29T21:24:34Z Pharminent en France 'first EU country to cover obesity drugs' 2026-05-28T13:11:36Z Blog https://pharminent.com/gsk-hails-unprecedented-cure-rates-with-hep-b-drug/ 2026-05-28T15:34:52Z Pharminent en GSK hails 'unprecedented' cure rates with hep B drug 2026-05-28T12:05:56Z Blog https://pharminent.com/abbvie-snags-fdas-first-adc-approval-for-ultra-rare-blood-cancer/ 2026-05-28T15:34:56Z Pharminent en AbbVie snags FDA's first ADC approval for ultra-rare blood cancer 2026-05-28T11:27:47Z Blog https://pharminent.com/november-date-set-for-fda-decision-on-sanofis-gaucher-drug/ 2026-05-30T21:30:34Z Pharminent en November date set for FDA decision on Sanofi's Gaucher drug 2026-05-28T10:11:11Z Blog